Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk
Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.
Stocks · News reference
Cramer Passes On NioCorp And SoundHound — But Says One Stock Is 'Time To Buy'
Jim Cramer recommends buying SOFI, and avoiding RIVN and BSX. He also says NIOBF is too speculative, but likes MP and INOD in the data engineering market.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)
The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.
Boston Scientific shares are trading lower after the FDA disclosed it is aware that the companyissued a letter to affected customers recommending all unused Infinion CX Leads be removed from where they are used or sold.
FDA Says Aware Boston Scientific Issued Letter To Affected Customers Recommending Unused Infinion CX Leads Be Removed From Where They Are Used/Sold; As Of May 27, 2026, Boston Scientific Reported 1,081 Serious Injuries And No Deaths Associated With Issue Related To Infinion CX Leads
Can Innodata's 49% Margin Become Its New AI Growth Benchmark Today?
Innodata (INOD) reported Q2 2026 revenues surging 58% to $92.1M with adjusted gross margins expanding to 49%, nine points above its 40% target. The company reiterated at least 40% revenue growth guidance for 2026, driven by AI programs including LLM training and agentic AI. Customer concentration improved with the largest customer declining to 37% of revenues from 56% in Q1.
Innodata vs. TaskUs: Which AI Services Stock Has Better Upside?
Innodata and TaskUs both capitalize on AI demand but with different profiles. Innodata shows stronger revenue growth (58% YoY) and expanding AI opportunities but trades at a premium 37.29X P/E with customer concentration risks. TaskUs offers cheaper valuation (5.24X P/E), better recent stock performance (+22.9% in 3 months), and solid cash generation, but slower overall growth (5% YoY). Innodata gets the edge for growth-focused investors, while TaskUs appeals to value investors.